Citigroup Calls Time on Moderna's Rally as Courtroom and Boardroom Pressures Mount
Published on 09/30/2026 at 20:30 | Editorial boerse-global.de
Moderna's blistering run has finally run into a wall of skepticism — and not just from the sell side.
Citigroup downgraded the biotech's shares from "Neutral" to "Sell" on Wednesday, citing valuation concerns after the stock's dramatic climb on the back of its oncology pipeline. The move stopped the rally in its tracks, with the stock sliding 6.0% to EUR 168.60 in European trading. Reuters reported that selling pressure had already built up in US premarket activity before the European session opened.
The downgrade carries an unusual twist: even as it cut its rating, Citigroup raised its price target from $60 to $80. In the bank's view, the current valuation already fully reflects optimism about Moderna's cancer programs — leaving little room for error.
A 535% Run Built on Cancer Hopes
The skepticism lands on a stock that has been nothing short of spectacular. Moderna has gained 535% since the start of the year, a surge powered largely by progress in personalized cancer therapies. The shares have come within 1.3% of their 52-week high, recently changing hands at EUR 181.54.
That enthusiasm has a clear catalyst. Roughly a week ago, Moderna disclosed that Phase 3 data for Intismeran Autogene in resected Stage IIB–IV melanoma had been selected for a symposium at the ESMO Congress. The company has scheduled an investor webcast for October 24, 2026, when the INTerpath-001 trial — testing the agent in combination with Keytruda — will be presented during a Presidential Symposium. The Madrid congress runs from October 23 to 27.
Should investors sell immediately? Or is it worth buying Moderna?
CEO Stéphane Bancel reinforced the strategic pivot away from COVID-19 vaccines at an industry conference on September 23. A day later, co-founder and Chairman Noubar Afeyan met with Saeed bin Mubarak Al Hajeri of the Emirates Drug Establishment to discuss potential research and production partnerships.
Delaware Court Keeps mRNA Patent Fight Alive
Adding to the valuation debate is a legal headache that refuses to go away. On Monday, a US federal judge in Delaware rejected Moderna's bid to dismiss a patent lawsuit brought by Bayer subsidiary Monsanto over alleged mRNA patent infringements. Pfizer and BioNTech failed in similar attempts in separate proceedings.
The ruling does not decide whether any patent was actually infringed or whether the protections themselves are valid — but it forces the vaccine makers to confront the claims on the merits. For a company whose core technology platform sits at the center of the dispute, the financial and strategic stakes could be substantial.
Bernstein Stands Apart With a $45 Target
Not everyone on Wall Street is chasing the momentum. On Friday, Bernstein reiterated its "Market Perform" rating with a price target of $45.00. Analyst Courtney Breen, speaking after the company's forum, flagged the commercial scale-up of Intismeran as the key open question.
The gulf between Bernstein's target and the stock's recent record highs illustrates just how far market pricing has drifted from the more cautious models of some industry observers.
Leadership Shuffle and Insider Selling
Moderna is also reshaping its executive ranks. In a regulatory filing, the company said Juan Andres will take on the newly created role of Chief Operating Officer effective October 5, 2026, overseeing global manufacturing and operational execution. Jerh Collins, previously responsible for technical operations and quality assurance, is retiring.
Moderna at a turning point? This analysis reveals what investors need to know now.
Separately, President Stephen Hoge sold shares under a pre-arranged trading plan. The transactions on September 14 and 15 covered a total of 80,575 shares.
A Stock Priced for Perfection
Taken together, the pressures form a double bind. The Delaware litigation compels Moderna to commit significant resources to defending its market position, while the entire weight of valuation now rests on the data set to be unveiled in Madrid on October 24.
With the shares priced almost perfectly for success, there is scant cushion for operational or legal setbacks. Any disappointment in the clinical presentation — even in the details — could leave the stock facing a considerable fall from its recent heights.
Ad
Moderna Stock: New Analysis - 30 September
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
